Report Cover

United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Report & Forecast 2021-2027


United States Glucagon Like Peptide-1 (GLP-1) Agonists Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment Percentages, By Type, 2020 (%)
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

United States Glucagon Like Peptide-1 (GLP-1) Agonists Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment Percentages, By Application, 2020 (%)
    Hospital
    Pharmacy
    Other

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glucagon Like Peptide-1 (GLP-1) Agonists revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Glucagon Like Peptide-1 (GLP-1) Agonists revenues share in United States market, 2020 (%)
Key companies Glucagon Like Peptide-1 (GLP-1) Agonists sales in United States market, 2016-2021 (Estimated), (K Units)
Key companies Glucagon Like Peptide-1 (GLP-1) Agonists sales share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Amylin
1 Introduction to Research & Analysis Reports
    1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Definition
    1.2 Market Segments
        1.2.1 Segment by Type
        1.2.2 Segment by Application
    1.3 United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
    1.4 Methodology & Sources of Information
        1.4.1 Research Methodology
        1.4.2 Research Process
        1.4.3 Base Year

2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Overall Market Size
    2.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Size: 2021 VS 2027
    2.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, Prospects & Forecasts: 2016-2027
    2.3 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales: 2016-2027

3 Company Landscape
    3.1 Top Glucagon Like Peptide-1 (GLP-1) Agonists Players in United States Market
    3.2 Top United States Glucagon Like Peptide-1 (GLP-1) Agonists Companies Ranked by Revenue
    3.3 United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Companies
    3.4 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Companies
    3.5 United States Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturer (2016-2021)
    3.6 Top 3 and Top 5 Glucagon Like Peptide-1 (GLP-1) Agonists Companies in United States Market, by Revenue in 2020
    3.7 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
    3.8 Tier 1, Tier 2 and Tier 3 Glucagon Like Peptide-1 (GLP-1) Agonists Players in United States Market
        3.8.1 List of Tier 1 Glucagon Like Peptide-1 (GLP-1) Agonists Companies in United States
        3.8.2 List of Tier 2 and Tier 3 Glucagon Like Peptide-1 (GLP-1) Agonists Companies in United States

4 Sights by Type
    4.1 Overview
        4.1.1 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Markets, 2021 & 2027
        4.1.2 Exenatied
        4.1.3 Liraglutide
        4.1.4 Lixisenatide
        4.1.5 Albiglutide
        4.1.6 Dulaglutide
    4.2 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue & Forecasts
        4.2.1 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2016-2021
        4.2.2 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2022-2027
        4.2.3 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share, 2016-2027
    4.3 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales & Forecasts
        4.3.1 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales, 2016-2021
        4.3.2 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales, 2022-2027
        4.3.3 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share, 2016-2027
    4.4 By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Price (Manufacturers Selling Prices), 2016-2027

5 Sights by Application
    5.1 Overview
        5.1.1 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, 2021 & 2027
        5.1.2 Hospital
        5.1.3 Pharmacy
        5.1.4 Other
    5.2 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue & Forecasts
        5.2.1 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2016-2021
        5.2.2 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2022-2027
        5.2.3 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share, 2016-2027
    5.3 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales & Forecasts
        5.3.1 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales, 2016-2021
        5.3.2 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales, 2022-2027
        5.3.3 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share, 2016-2027
    5.4 By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Price (Manufacturers Selling Prices), 2016-2027

6 Manufacturers & Brands Profiles
    6.1 Novo Nordisk
        6.1.1 Novo Nordisk Corporation Information
        6.1.2 Novo Nordisk Overview
        6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.1.5 Novo Nordisk Recent Developments
    6.2 AstraZeneca
        6.2.1 AstraZeneca Corporation Information
        6.2.2 AstraZeneca Overview
        6.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.2.5 AstraZeneca Recent Developments
    6.3 Eli Lily
        6.3.1 Eli Lily Corporation Information
        6.3.2 Eli Lily Overview
        6.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.3.5 Eli Lily Recent Developments
    6.4 GSK
        6.4.1 GSK Corporation Information
        6.4.2 GSK Overview
        6.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.4.5 GSK Recent Developments
    6.5 Sanofi
        6.5.1 Sanofi Corporation Information
        6.5.2 Sanofi Overview
        6.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.5.5 Sanofi Recent Developments
    6.6 Bristol-Myers Squibb
        6.6.1 Bristol-Myers Squibb Corporation Information
        6.6.2 Bristol-Myers Squibb Overview
        6.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.6.5 Bristol-Myers Squibb Recent Developments
    6.7 Amylin
        6.7.1 Amylin Corporation Information
        6.7.2 Amylin Overview
        6.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Revenue in United States Market (2016-2021)
        6.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Description
        6.7.5 Amylin Recent Developments

7 United States Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, Analysis
    7.1 United States Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity, 2016-2027
    7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity of Key Manufacturers in United States Market

8 Key Market Trends, Opportunity, Drivers and Restraints
    8.1 Market Opportunities & Trends
    8.2 Market Drivers
    8.3 Market Restraints

9 Glucagon Like Peptide-1 (GLP-1) Agonists Supply Chain Analysis
    9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Value Chain
    9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Upstream Market
    9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Downstream and Clients
    9.4 Marketing Channels Analysis
        9.4.1 Marketing Channels
        9.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors and Sales Agents in United States Market

10 Conclusion
11 Appendix
    11.1 Note
    11.2 Examples of Clients
    11.3 Author Details
    11.4 Disclaimer

List of Tables Table 1. Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists in United States Market Table 2. Top Glucagon Like Peptide-1 (GLP-1) Agonists Players in United States Market, Ranking by Revenue (2019) Table 3. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Companies, (US$, Mn), 2016-2021 Table 4. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Companies, 2016-2021 Table 5. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Companies, (K Units), 2016-2021 Table 6. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Companies, 2016-2021 Table 7. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Price (2016-2021) & (USD/Unit) Table 8. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type Table 9. List of Tier 1 Glucagon Like Peptide-1 (GLP-1) Agonists Companies, Revenue (US$, Mn) in 2020 and Market Share Table 10. List of Tier 2 and Tier 3 Glucagon Like Peptide-1 (GLP-1) Agonists Companies, Revenue (US$, Mn) in 2020 and Market Share Table 11. Major Manufacturers of Exenatied Table 12. Major Manufacturers of Liraglutide Table 13. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$, Mn), 2021 & 2027 Table 14. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$, Mn), 2016-2021 Table 15. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$, Mn), 2022-2027 Table 16. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), 2016-2021 Table 17. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), 2022-2027 Table 18. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$, Mn), 2021 VS 2027 Table 19. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$, Mn), 2016-2021 Table 20. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$, Mn), 2022-2027 Table 21. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), 2016-2021 Table 22. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), 2022-2027 Table 23. Novo Nordisk Corporation Information Table 24. Novo Nordisk Description and Major Businesses Table 25. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 26. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 27. Novo Nordisk Recent Developments Table 28. AstraZeneca Corporation Information Table 29. AstraZeneca Description and Major Businesses Table 30. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 31. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 32. AstraZeneca Recent Developments Table 33. Eli Lily Corporation Information Table 34. Eli Lily Description and Major Businesses Table 35. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 36. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 37. Eli Lily Recent Developments Table 38. GSK Corporation Information Table 39. GSK Description and Major Businesses Table 40. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 41. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 42. GSK Recent Developments Table 43. Sanofi Corporation Information Table 44. Sanofi Description and Major Businesses Table 45. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 46. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 47. Sanofi Recent Developments Table 48. Bristol-Myers Squibb Corporation Information Table 49. Bristol-Myers Squibb Description and Major Businesses Table 50. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 51. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 52. Bristol-Myers Squibb Recent Developments Table 53. Amylin Corporation Information Table 54. Amylin Description and Major Businesses Table 55. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$, Mn) and Gross Margin (USD/Unit) (2016-2021) Table 56. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Table 57. Amylin Recent Developments Table 58. Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity (K Units) of Key Manufacturers in United States Market, 2019-2021 (K Units) Table 59. United States Glucagon Like Peptide-1 (GLP-1) Agonists Capacity Market Share of Key Manufacturers, 2019-2021 Table 60. Glucagon Like Peptide-1 (GLP-1) Agonists Market Opportunities & Trends in United States Market Table 61. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers in United States Market Table 62. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints in United States Market Table 63. Glucagon Like Peptide-1 (GLP-1) Agonists Raw Materials Table 64. Glucagon Like Peptide-1 (GLP-1) Agonists Raw Materials Suppliers in United States Market Table 65. Typical Glucagon Like Peptide-1 (GLP-1) Agonists Downstream Table 66. Glucagon Like Peptide-1 (GLP-1) Agonists Downstream Clients in United States Market Table 67. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors and Sales Agents in United States Market List of Figures Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture Figure 2. Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type Figure 3. Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application Figure 4. United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview: 2020 Figure 5. United States Glucagon Like Peptide-1 (GLP-1) Agonists Market Size: 2021 VS 2027 (US$, Mn) Figure 6. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, 2016-2027 (US$, Mn) Figure 7. Glucagon Like Peptide-1 (GLP-1) Agonists Sales in United States Market: 2016-2027 (K Units) Figure 8. The Top 3 and 5 Players Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2020 Figure 9. Exenatied Product Picture Figure 10. Liraglutide Product Picture Figure 11. Lixisenatide Product Picture Figure 12. Albiglutide Product Picture Figure 13. Dulaglutide Product Picture Figure 14. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share, 2016-2027 Figure 15. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share, 2016-2027 Figure 16. By Type - United States Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit), 2016-2027 Figure 17. Hospital Figure 18. Pharmacy Figure 19. Other Figure 20. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share, 2016-2027 Figure 21. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share, 2016-2027 Figure 22. By Application - United States Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit), 2016-2027 Figure 23. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 24. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 25. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 26. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 27. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 28. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 29. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 30. United States Glucagon Like Peptide-1 (GLP-1) Agonists Production Capacity (K Units), 2016-2027 Figure 31. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Value Chain Figure 32. Marketing Channels

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us